# KPV: Research Overview — UK Peptides Lab > A literature summary of KPV (Lysine-Proline-Valine, alpha-MSH 11-13): mechanism via PepT1 and NF-kB suppression, murine colitis findings, formulation challenges, and regulatory status. Research-only, no medical advice. The anti-inflammatory C-terminal tripeptide of alpha-melanocyte-stimulating hormone — a preclinical-only compound studied in gut inflammation, with a mechanism built around the intestinal PepT1 transporter. ## The short version KPV stands for Lysine-Proline-Valine, the three amino acids that make up its sequence. It is the C-terminal (tail-end) tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), corresponding to positions 11 through 13 of that hormone. Researchers are interested in it because it appears to retain much of alpha-MSH's anti-inflammatory activity while shedding the parent hormone's melanogenic (skin-darkening, pigmentation) effect. This makes KPV a more targeted research tool for studying inflammation without the complication of pigmentation side effects. All of the evidence for KPV is preclinical — cell cultures and mouse models, chiefly of gut inflammation (colitis). There are no published human clinical trials of this compound. It is not approved as a drug or dietary supplement anywhere. Much recent research effort concerns formulation — how to deliver a very small, easily degraded tripeptide to a target tissue before peptidases break it down — rather than pharmacological efficacy itself. This page summarises that preclinical literature; it does not constitute medical advice and lists no human dose. ## What it is KPV is a linear tripeptide with molecular formula C₁₆H₃₀N₄O₄ and the sequence L-lysyl-L-prolyl-L-valine. It corresponds to residues 11-13 (the C-terminal tripeptide) of alpha-MSH, and this positional identity is often written as alpha-MSH(11-13). Alpha-MSH is a 13-amino-acid melanocortin hormone derived from the pro-opiomelanocortin (POMC) precursor; its well-characterised anti-inflammatory properties have long been attributed in part to this C-terminal sequence. Critically, KPV is **not** a melanocortin receptor agonist in the conventional sense. Research has demonstrated that it can reduce inflammation through an MC1R-independent mechanism — studies in MC1R-deficient mice show KPV retaining anti-inflammatory activity — distinguishing it clearly from melanocortin drugs that work through pigmentation or classical receptor pathways [11]. This is part of why it attracts interest as an anti-inflammatory tool: it appears to act downstream of receptor binding, through intracellular signalling pathways, rather than through melanocortin-receptor occupancy. As a tripeptide it is also very small and peptidase-labile — enzymes in the gut and blood rapidly cleave peptide bonds, so free KPV has a short half-life in biological environments. This fragility is the main practical limitation driving nanoparticle and hydrogel formulation research [9]. ## How it works KPV's mechanism is best understood at two levels: how it gets into cells, and what it does once there. **Cellular uptake via PepT1.** The di/tripeptide transporter PepT1 (gene: SLC15A1) is expressed on the apical surface of intestinal epithelial cells and is markedly upregulated in inflamed intestinal tissue. Research demonstrated that KPV is actively transported into epithelial cells and immune cells in the gut via PepT1, rather than by passive diffusion [10]. This is significant: it means KPV can reach intracellular targets directly, and that its delivery is amplified at sites of inflammation because PepT1 expression rises there. **Intracellular anti-inflammatory signalling.** Once inside the cell, KPV at nanomolar concentrations suppresses NF-kB — the master transcriptional regulator of inflammatory gene expression — as well as MAP kinase pathways that relay inflammatory signals [10]. The downstream consequence is reduced secretion of pro-inflammatory cytokines, particularly IL-1β and TNF-α. This pattern of suppressing both NF-kB and MAPK cascades is consistent with what the broader alpha-MSH literature describes for anti-inflammatory melanocortin action, though the exact intracellular binding partner for KPV has not been fully characterised [12]. ## What the research shows **Anti-inflammatory activity in multiple models (2008).** A comprehensive review of alpha-MSH and related tripeptides catalogued protective effects of KPV-related sequences across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic and organ-injury models [12]. The review delineated KPV as an anti-inflammatory research alternative to the full alpha-MSH molecule because it preserves anti-inflammatory activity while lacking melanogenic action — a critical functional distinction for research purposes. **PepT1-mediated uptake and NF-kB/MAPK suppression in colitis (2008).** The foundational mechanistic paper by Dalmasso and colleagues demonstrated that KPV is taken up into human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells via PepT1, that nanomolar concentrations reduced NF-kB and MAPK activation and decreased pro-inflammatory cytokine secretion in vitro, and that oral KPV reduced colitis severity in C57BL/6 mice in both DSS- and TNBS-induced models [10]. **MC1R-independent activity in murine IBD models (2008).** Kannengiesser and colleagues tested KPV in DSS-induced colitis and CD45RBhi adoptive-transfer colitis models and found KPV-treated mice showed earlier recovery, significantly better regain of body weight, and reduced colonic inflammatory infiltrate and myeloperoxidase activity. Importantly, the anti-inflammatory effect was retained in MC1R-deficient mice, confirming that KPV's action does not depend on melanocortin-1 receptor binding [11]. **Targeted nanoparticle delivery for colitis (2017).** Xiao and colleagues addressed KPV's fragility by encapsulating it in hyaluronic-acid-functionalised nanoparticles embedded in a chitosan/alginate oral hydrogel system. This targeted delivery vehicle directed KPV to inflamed colon tissue, reduced colitis severity more effectively than non-targeted formulations, decreased TNF-α expression, and accelerated mucosal healing [9]. The work represents a proof-of-concept for how formulation can overcome KPV's peptidase-lability problem, but it was conducted in mice. **Combination KPV/FK506 nanodrug (2024).** A more recent study co-assembled KPV with the immunosuppressant FK506 in a PepT1-targeted nanodrug and showed improvements in both acute and chronic mouse colitis models beyond either compound alone, including restoration of tight-junction proteins and further reduction of inflammatory cytokines [8]. This line of formulation research continues, but all evidence remains in rodent models. ## Reported effects, cautions and safety **On anecdotal reports:** KPV does not have an established community of human research users comparable to those for Thymosin Alpha-1 or BPC-157. The compound is primarily present in academic literature and laboratory supply catalogues; community-reported human experience is minimal and largely anecdotal accounts from individuals using it for gut complaints. No systematic collection of user reports exists. The absence of human clinical data means there is no basis on which to describe typical human effects. **Research caveats and structural limitations:** - *No human clinical trials exist.* The entire efficacy record for KPV is in vitro and in rodent models. Human dosing, bioavailability, pharmacokinetics, and safety are entirely unestablished. - *Peptidase lability.* As a free tripeptide, KPV is rapidly degraded in biological fluids. The delivery problem has not been solved for human use; nanoparticle formulations that work in mice have not been validated in people. - *Independent replication.* Much of the mechanistic work traces to a small number of laboratories. Wider independent replication would strengthen the preclinical case. - *Regulatory status.* KPV is available only as a research chemical for laboratory use; it is not approved as a drug or dietary supplement in any jurisdiction. There is no validated human therapeutic indication. - *Marketing outpaces evidence.* Claims attributing skin, gut, or systemic anti-inflammatory benefits to KPV in human consumers go well beyond what the preclinical literature demonstrates. ## Where it fits in immune and tissue-repair research Within this desk's framework, KPV occupies the middle register of the immune-to-repair cascade. Where [Thymosin Alpha-1](/thymosin-alpha-1) acts at the systemic level to orchestrate adaptive immune output, KPV operates locally — at the mucosal surface of inflamed tissue — to quieten the NF-kB-driven signalling that sustains inflammatory damage. In an inflamed gut, the contribution of local signal-suppression to overall repair is significant; without resolving that inflammatory microenvironment, structural tissue healing is impaired. [BPC-157](/bpc-157) then acts further downstream in the repair sequence, promoting the vascular remodelling and angiogenesis that bring nutrients and oxygen to healing tissue. The three together — immune orchestration, local inflammation control, vascular repair — represent distinct but complementary research angles on the same fundamental problem. [Compare all three](/compare) on the compare page. --- A structured cross-reference of published research literature on immune and tissue-repair peptides — not a laboratory, not a vendor, and not a source of medical or dosing advice.